1. Home
  2. GANX vs RPID Comparison

GANX vs RPID Comparison

Compare GANX & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • RPID
  • Stock Information
  • Founded
  • GANX 2017
  • RPID 2006
  • Country
  • GANX United States
  • RPID United States
  • Employees
  • GANX N/A
  • RPID N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • RPID Medical Specialities
  • Sector
  • GANX Health Care
  • RPID Health Care
  • Exchange
  • GANX Nasdaq
  • RPID Nasdaq
  • Market Cap
  • GANX 41.9M
  • RPID 43.5M
  • IPO Year
  • GANX 2021
  • RPID 2021
  • Fundamental
  • Price
  • GANX $2.27
  • RPID $3.21
  • Analyst Decision
  • GANX Strong Buy
  • RPID Buy
  • Analyst Count
  • GANX 5
  • RPID 1
  • Target Price
  • GANX $7.60
  • RPID $8.00
  • AVG Volume (30 Days)
  • GANX 218.6K
  • RPID 583.3K
  • Earning Date
  • GANX 03-25-2025
  • RPID 02-28-2025
  • Dividend Yield
  • GANX N/A
  • RPID N/A
  • EPS Growth
  • GANX N/A
  • RPID N/A
  • EPS
  • GANX N/A
  • RPID N/A
  • Revenue
  • GANX N/A
  • RPID $26,170,000.00
  • Revenue This Year
  • GANX N/A
  • RPID $25.32
  • Revenue Next Year
  • GANX N/A
  • RPID $18.92
  • P/E Ratio
  • GANX N/A
  • RPID N/A
  • Revenue Growth
  • GANX N/A
  • RPID 27.31
  • 52 Week Low
  • GANX $0.89
  • RPID $0.58
  • 52 Week High
  • GANX $5.19
  • RPID $4.04
  • Technical
  • Relative Strength Index (RSI)
  • GANX 47.71
  • RPID 62.15
  • Support Level
  • GANX $2.30
  • RPID $3.38
  • Resistance Level
  • GANX $2.81
  • RPID $4.04
  • Average True Range (ATR)
  • GANX 0.25
  • RPID 0.51
  • MACD
  • GANX -0.03
  • RPID 0.04
  • Stochastic Oscillator
  • GANX 35.33
  • RPID 64.11

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.

Share on Social Networks: